Biodesix Closes Series D Financing - July 2011
Biodesix has closed a $20 million series D financing. The new capital will support ongoing commercialization activities for the company's Veristrat.
254 Results
Biodesix has closed a $20 million series D financing. The new capital will support ongoing commercialization activities for the company's Veristrat.
Biodesix is one of 30 companies chosen to present at the regional conference held biennially by the Colorado BioScience Association (CBSA).
Publication announced today: Changes in plasma mass-spectral (VeriStrat) profile in course of treatment of NSCLC patients with EGFR-TKIs.
A retrospective analysis of serum samples from the phase III study, EGF30008, will be presented at the 34th Annual San Antonio Breast Cancer Symposium SABCS.
Biodesix received the Product Differentiation Excellence Award for its accomplishments in the cancer diagnostics industry.
Biodesix announced the issuance of three additional patents. Two which provide intellectual property protection and the other for Veristrat.
Data show that VeriStrat was able to stratify renal cell carcinoma (RCC) patients treated with a combination of two targeted therapies.
Veristrat can be used to identify a group of patients with worse progression-free (PFS) when treated with Femera alone, independent of Her2 status.
The initiation of two strategic partnerships that will provide cancer patients greater and more convenient options for completing VeriStrat testing.
Biodesix today announced a collaboration with Kadmon Corporation, LLC, to explore the utility of Biodesix’ VeriStrat® test in a Phase 3 (NSCLC).